Halozyme, Baxter Get Promising Morphine Study Results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Halozyme Therapeutics, Inc. and Baxter Healthcare achieved positive results from a Phase IIIB trial showing that subcutaneous administration of morphine with Hylenex recombinant (hyaluronidase human injection) accelerated the time to maximal blood levels of morphine by 33% versus morphine with placebo. The formulation also appeared to be safe and well tolerated. Hylenex recombinant is a liquid injectable formulation that includes the API, recombinant human hyaluronidase (rHuPH20), which is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters